Skip to content
10-Q

Quarterly Report

BIOFORCE NANOSCIENCES HOLDINGS, INC. BFNH

0001091818-23-000181

← back to feed
Filed
Nov 3, 2023 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2023 · Oct 31, 2023 29.27M sh
Cash And Equivalents Q3 2023 · Sep 30, 2023 $686
Cash And Equivalents Q3 2023 · Dec 31, 2022 $734
Current Liabilities Q3 2023 · Sep 30, 2023 $1.71M
Current Liabilities Q3 2023 · Dec 31, 2022 $1.35M
Total Liabilities Q3 2023 · Sep 30, 2023 $1.71M
Total Liabilities Q3 2023 · Dec 31, 2022 $1.35M
Current Assets Q3 2023 · Sep 30, 2023 $686
Current Assets Q3 2023 · Dec 31, 2022 $734
Total Assets Q3 2023 · Sep 30, 2023 $686
Total Assets Q3 2023 · Dec 31, 2022 $734
Shares Diluted Q3 2023 · Sep 30, 2022 29.27M sh
Shares Diluted Q3 2023 · Sep 30, 2022 29.27M sh
Operating Cash Flow Q3 2023 · Sep 30, 2022 −$58.96K
Stockholders Equity Q3 2023 · Sep 30, 2022 −$1.23M
Stockholders Equity Q3 2023 · Jun 30, 2022 −$1.11M
Stockholders Equity Q3 2023 · Mar 31, 2022 −$994.27K
Stockholders Equity Q3 2023 · Dec 31, 2021 −$861.86K
Eps Diluted Q3 2023 · Sep 30, 2022 $0.00
Eps Diluted restated Q3 2023 · Sep 30, 2022 $0.01
Eps Basic Q3 2023 · Sep 30, 2022 $0.00
Eps Basic restated Q3 2023 · Sep 30, 2022 $0.01
Sga Expense Q3 2023 · Sep 30, 2022 $16.84K
Sga Expense Q3 2023 · Sep 30, 2022 $53.53K
Net Income Q3 2023 · Sep 30, 2022 −$122.59K
Net Income Q3 2023 · Sep 30, 2022 −$370.78K